Vicore Pharma Ab (publ)(NASDAQ) VCRE

Market CapN/A

Since IPO (2026)-32%

5 YearN/A

1 YearN/A

1 Month-3%

$11.04

-2.39%

-0.27Today

Vicore Pharma Ab (publ) last closing stock price
Metric	Price	Date
Last close	USD 11.04	2026-08-31

Vicore Pharma Ab (publ) stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4%	USD 11.50	2026-08-24
1 month	-3.16%	USD 11.40	2026-07-31
Since inception	-32.06%	USD 16.25	2026-07-06

Vicore Pharma Ab (publ) Financials at a Glance

Market Cap

N/A

Revenue (TTM)

SEK 1.33M

Net Income (TTM)

-SEK 272.50M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.04

Volume

9,579

Open

$10.74

Price

$11.04

Volume

9,579

Open

$10.74

Previous Close

$11.04

Daily Range

$10.70 - $11.04

52-Week Range

$10.50 - $17.80

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.04

Volume

9,579

Open

$10.74

Previous Close

$11.04

Daily Range

$10.70 - $11.04

52-Week Range

$10.50 - $17.80

Estimated Earnings Date

Nov 5, 2026

VCRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vicore Pharma Ab (publ)

Vicore Pharma Holding AB is a pharmaceutical company focused on developing innovative drugs for interstitial lung diseases and related indications. Founded in 2000 and headquartered in Stockholm, Sweden, the company is dedicated to addressing unmet medical needs in the healthcare sector.

Products and Services

VP01: A drug targeting interstitial lung diseases
VP02: Focused on related respiratory conditions
VP03 and VP04: Additional drug development programs in the pipeline

Growth Outlook

Market cap of approximately $3.58 billion indicates strong investor interest
Stock price range between $10.5 and $17.8 shows potential for growth
Low beta of 0.149 suggests stability compared to the overall market

Financial Highlights

Recent stock price of $12.73 reflects positive market sentiment
Volume of 43,090 shares traded indicates active investor engagement
No dividends paid, allowing for reinvestment in growth initiatives

Vicore Pharma Holding AB is positioned in the biotechnology industry, focusing on critical areas of healthcare. The company's commitment to developing treatments for interstitial lung diseases is underscored by its diverse pipeline of drug candidates. The strong market capitalization and active trading volume suggest a robust interest from investors, while the stock's price stability may appeal to those seeking lower volatility in the biotechnology sector. The absence of dividends allows the company to reinvest in its growth strategies, potentially enhancing long-term value for shareholders.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Stockholm, AB 111 27, SE

VCRE Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-21455.42%

Net Income Margin

-20489.51%

Return on Equity

-48.25%

Return on Capital

-41.48%

Return on Assets

-284.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

9.58K

Avg. Volume

25.71K

Financials (TTM)

Gross Profit

SEK 1.33M

Operating Income

-SEK 285.35M

EBITDA

-SEK 248.71M

Operating Cash Flow

-SEK 225.86M

Capital Expenditure

SEK 0.00

Free Cash Flow

-SEK 225.86M

Cash & ST Invst.

SEK 93.41M

Total Debt

SEK 0.00

Vicore Pharma Ab (publ) Performance Analysis

Vicore Pharma Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-95.4%
Q4	2025-12-31	419.0%
Q1	2026-03-31	43.7%
Q2	2026-06-30	-62.1%

Vicore Pharma Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	99.0%
Q4	2025-12-31	-10405.8%
Q1	2026-03-31	27.8%
Q2	2026-06-30	98.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

SEK 228.25K

-86.9%

Gross Profit

SEK 228.25K

-86.9%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-SEK 14.73M

+87.2%

EBITDA

SEK 0.00

+100.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

SEK 93.41M

N/A

Total Debt

SEK 0.00

N/A

Accounts Receivable

SEK 0.00

N/A

Inventory

SEK 0.00

N/A

Long Term Debt

SEK 0.00

N/A

Short Term Debt

SEK 0.00

N/A

Return on Assets

-2.84%

N/A

Return on Invested Capital

-3.23%

N/A

Free Cash Flow

-SEK 16.08M

+84.9%

Operating Cash Flow

-SEK 16.08M

+84.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About VCRE

What is the current price of Vicore Pharma Ab (publ)?

Vicore Pharma Ab (publ) is trading at $11.04 per share.

What is the 52-week range for Vicore Pharma Ab (publ)?

Over the past 52 weeks, Vicore Pharma Ab (publ) has traded between $10.50 and $17.80.

How much debt does Vicore Pharma Ab (publ) have?

Vicore Pharma Ab (publ) total debt is unavailable.

How much cash does Vicore Pharma Ab (publ) have on hand?

Vicore Pharma Ab (publ) does not have cash on hand data available.

What is Vicore Pharma Ab (publ)’s dividend yield?

Vicore Pharma Ab (publ) does not currently have a dividend yield.

Vicore Pharma Ab (publ)(NASDAQ) VCRE

Vicore Pharma Ab (publ) Financials at a Glance

VCRE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Vicore Pharma Ab (publ)

VCRE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Vicore Pharma Ab (publ) Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VCRE

What is the current price of Vicore Pharma Ab (publ)?

What is the 52-week range for Vicore Pharma Ab (publ)?

How much debt does Vicore Pharma Ab (publ) have?

How much cash does Vicore Pharma Ab (publ) have on hand?

What is Vicore Pharma Ab (publ)’s dividend yield?

Premium Investing Services